Döhner, HartmutDiNardo, Courtney DWei, Andrew HLöwenberg, BobAppelbaum, FrederickCraddock, CharlesDombret, HervéEbert, Benjamin LFenaux, PierreGodley, Lucy AHasserjian, Robert PLarson, Richard ALevine, Ross LMiyazaki, YasushiNiederwieser, DietgerOssenkoppele, Gert JRöllig, ChristophSierra, JorgeStein, Eytan MTallman, Martin STien, Hwei-FangWang, JianxiangWierzbowska, Agnieszka2024-09-132024-09-132024-08-12Döhner H, DiNardo CD, Wei AH, Löwenberg B, Appelbaum F, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024 Aug 12:blood.2024025409.1528-002010.1182/blood.202402540939133932http://hdl.handle.net/20.500.14200/5734The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.enCopyright © 2024 American Society of Hematology.HaematologyArticleBlood